Both Takeda and Daiichi Sankyo signs sales deals for Kaketsuken flu vaccine

Japanese drug majors Takeda Pharmaceutical (TYO: 4502) and Daiichi Sankyo (TYO: 4568) have both entered into an agreement with the Chemo-Sero-Therapeutic Research Institute (“Kaketsuken”) for distribution of the latter’s seasonal influenza vaccine (Influenza HA Vaccine “Kakeketsuken” in Japan, beginning in the upcoming season, 2015-2016.

Seasonal influenza typically occurs from early winter through early spring. Although most people quickly recover, there is a risk of progression to pneumonia, bronchitis and life-threatening severe complications, particularly in elderly individuals. As vaccination can protect against influenza infection and suppress the severity of symptoms, the Preventive Vaccination Law in Japan stipulates that the elderly are to receive regular vaccination. Given the aging population in Japan, the demand for seasonal influenza vaccine is increasing.

“We are pleased to have concluded a sales agreement on seasonal influenza vaccine with Kaketsuken. The Agreement will bolster our supply of influenza vaccine and allow us to meet the demand of as many patients and medical professionals as possible,” said Hitoshi Oinuma, head of the Japan Vaccine Business Unit of Takeda.

In 2014, Takeda received approval for the new drug application of Cell Culture-based Influenza vaccine for prevention of pandemic influenza, and is currently developing a cell culture-based seasonal influenza vaccine (Development code: TAK-850).

In addition, Daiichi Sankyo says it will continue to sell its current influenza HA vaccine, "Kitasatodaiichisankyo."